普萘洛尔治疗婴儿血管瘤的研究进展

doi:10.35541/cjd.20191042

中华皮肤科杂志 ›› 2020, Vol. 53 ›› Issue (7): 573-576.doi: 10.35541/cjd.20191042

普萘洛尔治疗婴儿血管瘤的研究进展

姜集聪¹,吴建洺¹,高宇²

1. 温州医科大学附属第二医院
2. 温州医学院附属第二医院皮肤科

收稿日期:2019-10-31 修回日期:2020-05-22 发布日期:2020-07-06
通讯作者: 高宇 E-mail:gaoyu0570@163.com
基金资助:
温州市基础性科研项目

Propranolol for the treatment of infantile hemangioma

Ji cong Jiang¹,Jianming Wu¹,

Received:2019-10-31 Revised:2020-05-22 Published:2020-07-06
Supported by:
Wenzhou Basic Research Project

摘要/Abstract

摘要： 【摘要】普萘洛尔是非选择性β肾上腺素受体阻滞剂，多项研究已证实其治疗婴儿血管瘤安全有效，作用机制主要包括：①由周细胞介导的血流动力学改变及后续效应；②阻滞血管瘤来源的内皮细胞和干细胞的细胞周期进程从而抑制其增殖，诱导血管瘤来源的内皮细胞凋亡和血管瘤来源的干细胞向脂肪细胞分化；③抑制内皮祖细胞的募集；④降低促血管生成因子（如血管内皮生长因子、基质金属蛋白酶等）的水平。

关键词: 血管瘤, 婴儿, 普萘洛尔, 血流动力学, 内皮细胞, 血管内皮生长因子类, 基质金属蛋白酶类

Abstract: 【Abstract】 Propranolol is a non-selective β-adrenoceptor blocker. Various studies have confirmed that it is safe and effective for the treatment of infantile hemangioma. The mechanism of action mainly includes: （1） pericyte-mediated hemodynamic changes and subsequent effects; （2） inhibiting proliferation of hemangioma-derived endothelial cells and stem cells by blocking cell cycle progression, inducing apoptosis of hemangioma-derived endothelial cells and differentiation of hemangioma-derived stem cells into adipocytes; （3） inhibiting the recruitment of endothelial progenitor cells; （4） reducing levels of pro-angiogenic factors, such as vascular endothelial growth factor, matrix metalloproteinase, etc.

Key words: Hemangioma, Infant, Propranolol, Hemodynamics, Endothelial cells, Vascular endothelial growth factors, Matrix metalloproteinases

姜集聪吴建洺高宇. 普萘洛尔治疗婴儿血管瘤的研究进展[J]. 中华皮肤科杂志, 2020,53(7):573-576. doi:10.35541/cjd.20191042

Ji cong Jiang Jianming Wu. Propranolol for the treatment of infantile hemangioma[J]. Chinese Journal of Dermatology, 2020, 53(7): 573-576.doi:10.35541/cjd.20191042

参考文献 40

［1］	张堂德, 李龙年, 邓俐. 婴儿血管瘤系统性治疗的一线药物:普萘洛尔［J］. 中华皮肤科杂志, 2011,44（4）:294⁃296. doi: 10.3760/cma.j.issn.0412⁃4030.2011.04.027
［2］	于鲁, 李丽, 马琳. 口服普萘洛尔治疗婴儿血管瘤的近期和远期安全性［J］. 中华皮肤科杂志, 2019,52（8）:586⁃589. doi:10.3760/cma.j.issn.0412⁃4030.2019.08.019
［3］	Lee D, Boscolo E, Durham JT, et al. Propranolol targets the contractility of infantile haemangioma⁃derived pericytes［J］. Br J Dermatol, 2014,171（5）:1129⁃1137. doi: 10.1111/bjd.13048.
［4］	Alarcon⁃Martinez L, Yilmaz⁃Ozcan S, Yemisci M, et al. Capillary pericytes express α⁃smooth muscle actin, which requires prevention of filamentous⁃actin depolymerization for detection［J/OL］. Elife, 2018,7:e34861. doi: 10.7554/eLife.34861.
［5］	Hirunpattarasilp C, Attwell D, Freitas F. The role of pericytes in brain disorders: from the periphery to the brain［J］. J Neurochem, 2019,150（6）:648⁃665. doi: 10.1111/jnc.14725.
［6］	Alarcon⁃Martinez L, Yilmaz⁃Ozcan S, Yemisci M, et al. Retinal ischemia induces α⁃SMA⁃mediated capillary pericyte contraction coincident with perivascular glycogen depletion［J］.Acta Neuropathol Commun,2019,7（1）:134. doi: 10.1186/s40478⁃019⁃0761⁃z.
［7］	Methner C, Mishra A, Golgotiu K, et al. Pericyte constriction underlies capillary derecruitment during hyperemia in the setting of arterial stenosis［J］. Am J Physiol Heart Circ Physiol, 2019,317（2）:H255⁃H263. doi: 10.1152/ajpheart.00097.2019.
［8］	Pan WK, Li P, Guo ZT, et al. Propranolol induces regression of hemangioma cells via the down⁃regulation of the PI3K/Akt/eNOS/VEGF pathway［J］. Pediatr Blood Cancer, 2015,62（8）:1414⁃1420. doi: 10.1002/pbc.25453.
［9］	Babendreyer A, Molls L, Simons IM, et al. The metalloproteinase ADAM15 is upregulated by shear stress and promotes survival of endothelial cells［J］. J Mol Cell Cardiol, 2019,134:51⁃61. doi: 10.1016/j.yjmcc.2019.06.017.
［10］	Kutikhin AG, Sinitsky MY, Yuzhalin AE, et al. Shear stress: an essential driver of endothelial progenitor cells［J］. J Mol Cell Cardiol, 2018,118:46⁃69. DOI: 10.1016/j.yjmcc.2018.03.007.
［11］	Hu Q, Zhang T, Li Y, et al. β2AR⁃dependent signaling contributes to in⁃vivo reendothelialization capacity of endothelial progenitor cells by shear stress［J］. J Hypertens, 2020,38（1）:82⁃94. doi: 10.1097/HJH.0000000000002203.
［12］	Huang J, Jiang D, Zhao S, et al. Propranolol suppresses infantile hemangioma cell proliferation and promotes apoptosis by upregulating miR⁃125b expression［J］. Anticancer Drugs, 2019,30（5）:501⁃507. doi: 10.1097/CAD.0000000000000762.
［13］	Razon MJ, Kräling BM, Mulliken JB, et al. Increased apoptosis coincides with onset of involution in infantile hemangioma［J］. Microcirculation, 1998,5（2⁃3）:189⁃195.
［14］	Tu JB, Ma RZ, Dong Q, et al. Induction of apoptosis in infantile hemangioma endothelial cells by propranolol［J］. Exp Ther Med, 2013,6（2）:574⁃578. doi: 10.3892/etm.2013.1159.
［15］	Yao TH, Pataer P, Regmi KP, et al. Propranolol induces hemangioma endothelial cell apoptosis via a p53‑BAX mediated pathway［J］. Mol Med Rep, 2018,18（1）:684⁃694. doi: 10.3892/mmr.2018.9013.
［16］	Chim H, Armijo BS, Miller E, et al. Propranolol induces regression of hemangioma cells through HIF⁃1α⁃mediated inhibition of VEGF⁃A［J］. Ann Surg, 2012,256（1）:146⁃156. doi: 10.1097/SLA.0b013e318254ce7a.
［17］	Lamy S, Lachambre MP, Lord⁃Dufour S, et al. Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells［J］. Vascul Pharmacol, 2010,53（5⁃6）:200⁃208. doi: 10.1016/j.vph.2010.08. 002.
［18］	Sun B, Dong C, Lei H, et al. Propranolol inhibits proliferation and invasion of hemangioma⁃derived endothelial cells by suppressing the DLL4/Notch1/Akt pathway［J］. Chem Biol Interact, 2018,294:28⁃33. doi: 10.1016/j.cbi.2018.08.018.
［19］	Khan ZA, Boscolo E, Picard A, et al. Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice［J］. J Clin Invest, 2008,118（7）:2592⁃2599. doi: 10.1172/JCI33493.
［20］	Overman J, Fontaine F, Wylie⁃Sears J, et al. R⁃propranolol is a small molecule inhibitor of the SOX18 transcription factor in a rare vascular syndrome and hemangioma［J/OL］. Elife, 2019,8:e43026. doi: 10.7554/eLife.43026.
［21］	Yuan SM, Guo Y, Wang Q, et al. Over⁃expression of PPAR⁃gamma2 gene enhances the adipogenic differentiation of hemangioma⁃derived mesenchymal stem cells in vitro and in vivo［J］. Oncotarget, 2017,8（70）:115817⁃115828. doi: 10.18632/oncotarget.23705.
［22］	Farzaneh M, Attari F, Khoshnam SE. Concise review: LIN28/let⁃7 signaling, a critical double⁃negative feedback loop during pluripotency, reprogramming, and tumorigenicity［J］. Cell Reprogram, 2017,19（5）:289⁃293. doi: 10.1089/cell.2017.0015.
［23］	Mong EF, Akat KM, Canfield J, et al. Modulation of LIN28B/Let⁃7 signaling by propranolol contributes to infantile hemangioma involution［J］. Arterioscler Thromb Vasc Biol, 2018,38（6）:1321⁃1332. doi: 10.1161/ATVBAHA.118.310908.
［24］	Kum JJ, Khan ZA. Propranolol inhibits growth of hemangioma⁃initiating cells but does not induce apoptosis［J］. Pediatr Res, 2014,75（3）:381⁃388. doi: 10.1038/pr.2013.231.
［25］	Kleinman ME, Greives MR, Churgin SS, et al. Hypoxia⁃induced mediators of stem/progenitor cell trafficking are increased in children with hemangioma［J］. Arterioscler Thromb Vasc Biol, 2007,27（12）:2664⁃2670. doi: 10.1161/ATVBAHA.107.150284.
［26］	Zuccolo E, Bottino C, Diofano F, et al. Constitutive store⁃operated Ca（2+） entry leads to enhanced nitric oxide production and proliferation in infantile hemangioma⁃derived endothelial colony⁃forming cells［J］. Stem Cells Dev, 2016,25（4）:301⁃319. doi: 10.1089/scd.2015.0240.
［27］	Moccia F, Negri S, Shekha M, et al. Endothelial Ca2+ signaling, angiogenesis and vasculogenesis: just what it takes to make a blood vessel［J］. Int J Mol Sci, 2019,20（16）:3962. doi: 10.3390/ijms20163962.
［28］	Zou HX, Jia J, Zhang WF, et al. Propranolol inhibits endothelial progenitor cell homing: a possible treatment mechanism of infantile hemangioma［J］. Cardiovasc Pathol, 2013,22（3）:203⁃210. doi: 10.1016/j.carpath.2012.10.001.
［29］	Campanelli R, Codazzi AC, Poletto V, et al. Kinetic and angiogenic activity of circulating endothelial colony forming cells in patients with infantile haemangioma receiving propranolol［J］. Thromb Haemost, 2019,119（2）:274⁃284. doi: 10.1055/s⁃0038⁃1676855.
［30］	Babiak⁃Choroszczak L, Gizewska⁃Kacprzak K, Gawrych E, et al. Serum concentrations of VEGF and bFGF in the course of propranolol therapy of infantile hemangioma in children: are we closer to understand the mechanism of action of propranolol on hemangiomas?［J］. Adv Clin Exp Med, 2018,27（5）:703⁃710. doi: 10.17219/acem/84800
［31］	Feliers D, Chen X, Akis N, et al. VEGF regulation of endothelial nitric oxide synthase in glomerular endothelial cells［J］. Kidney Int, 2005,68（4）:1648⁃1659. doi: 10.1111/j.1523⁃1755.2005.00 575.x.
［32］	Wang Y, Nagase S, Koyama A. Stimulatory effect of IGF⁃I and VEGF on eNOS message, protein expression, eNOS phosphorylation and nitric oxide production in rat glomeruli, and the involvement of PI3⁃K signaling pathway［J］. Nitric Oxide, 2004,10（1）:25⁃35. doi: 10.1016/j.niox.2004.02.001.
［33］	Medici D, Olsen BR. Rapamycin inhibits proliferation of hemangioma endothelial cells by reducing HIF⁃1⁃dependent expression of VEGF［J/OL］. PLoS One, 2012,7（8）:e42913. doi: 10.1371/journal.pone.0042913.
［34］	Chen YZ, Bai N, Bi JH, et al. Propranolol inhibits the proliferation, migration and tube formation of hemangioma cells through HIF⁃1α dependent mechanisms［J］. Braz J Med Biol Res, 2017,50（12）:e6138. doi: 10.1590/1414⁃431X20176138.
［35］	Li D, Li P, Guo Z, et al. Downregulation of miR⁃382 by propranolol inhibits the progression of infantile hemangioma via the PTEN⁃mediated AKT/mTOR pathway［J］. Int J Mol Med, 2017,39（3）:757⁃763. doi: 10.3892/ijmm.2017.2863.
［36］	Kumar N, Prasad P, Jash E, et al. Insights into exchange factor directly activated by cAMP （EPAC） as potential target for cancer treatment［J］. Mol Cell Biochem, 2018,447（1⁃2）:77⁃92. doi: 10.1007/s11010⁃018⁃3294⁃z.
［37］	Conlon GA, Murray GI. Recent advances in understanding the roles of matrix metalloproteinases in tumour invasion and metastasis［J］. J Pathol, 2019,247（5）:629⁃640. doi: 10.1002/path.5225.
［38］	Taran K, Wnęk A, Kobos J, et al. Tissue and serum mRNA profile of MMPs⁃2/9 as a potential novel biomarker for the most individual approach in infantile hemangiomas and cancer disease［J］. Immunobiology, 2017,222（11）:1035⁃1042. doi: 10.1016/j.imbio.2017.05.014.
［39］	Xu W, Li S, Yu F, et al. Role of thrombospondin⁃1 and nuclear factor⁃κb signaling pathways in antiangiogenesis of infantile hemangioma［J］. Plast Reconstr Surg,2018,142（3）:310e⁃321e. doi: 10.1097/PRS.0000000000004684.
［40］	Zhu L, Xie J, Liu Z, et al. Pigment epithelium⁃derived factor/vascular endothelial growth factor ratio plays a crucial role in the spontaneous regression of infant hemangioma and in the therapeutic effect of propranolol［J］. Cancer Sci, 2018,109（6）:1981⁃1994. doi: 10.1111/cas.13611.

[1]	王敏何萍秀程丽芳洪克春艾勇. 头皮脑（脊）膜错构瘤1例[J]. 中华皮肤科杂志, 2023, 56(5): 449-450.
[2]	杨开颖龚雪邱桐周江元兰钰茹吉毅. 糖酵解关键酶PFKFB3对婴幼儿血管瘤内皮细胞增殖、迁移及凋亡的影响[J]. 中华皮肤科杂志, 2023, 56(4): 320-324.
[3]	闫娜陈婷耿松梅李政霄刘燕马迎新谭宣丰. 皮下非对称减张联合真皮埋没成角褥式缝合在婴幼儿面部良性色素性皮损手术治疗中的应用[J]. 中华皮肤科杂志, 2023, 0(4): 20210659-e20210659.
[4]	张莉宋秀祖. 血管内皮生长因子在雄激素性脱发中的研究进展[J]. 中华皮肤科杂志, 2023, 0(2): 20220240-e20220240.
[5]	谢德琼杨开颖杨旸陈思源吉毅. 长链非编码RNA在婴幼儿血管瘤中的研究进展[J]. 中华皮肤科杂志, 2023, 56(12): 1173-1176.
[6]	邱桐杨开颖龚雪周江元张学鹏兰钰茹陈思源吉毅. 婴幼儿血管瘤相关危险因素的多中心病例对照研究[J]. 中华皮肤科杂志, 2022, 55(9): 772-777.
[7]	夏娜高超刘璇邹东旭姬广聚蔡宏. 脐带间充质干细胞外泌体对急性皮肤创面愈合的初步研究[J]. 中华皮肤科杂志, 2022, 55(5): 382-388.
[8]	杨开颖邱桐龚雪兰钰茹周江元陈思源吉毅. 白藜芦醇对婴儿血管瘤内皮细胞活性的影响[J]. 中华皮肤科杂志, 2022, 55(11): 990-995.
[9]	吴卓璇李蒙陈瑶刘佳琳胡枫覃莉. 分娩和喂养方式对特应性皮炎婴儿肠道菌群的影响[J]. 中华皮肤科杂志, 2022, 55(11): 976-981.
[10]	王文明贾倩楠方凯曾跃平. 血管内大B细胞淋巴瘤4例临床病理分析[J]. 中华皮肤科杂志, 2022, 55(1): 27-30.
[11]	何畑蓉刘运强杨元. 一例火棉胶样婴儿TGM1基因变异的致病性研究[J]. 中华皮肤科杂志, 2021, 54(8): 712-715.
[12]	武亚丽梅娟赵玲霞尹薇. 新生儿Goltz综合征PORCN基因新发突变一例[J]. 中华皮肤科杂志, 2021, 54(6): 514-517.
[13]	杨景煜顾珈榕郭静杨瑞王文成李云凤徐平顾金海. 皮肤黑素瘤细胞与血管内皮细胞间VEGF-IL-6-STAT3信号交互作用机制[J]. 中华皮肤科杂志, 2021, 54(4): 294-299.
[14]	朱雅琳万学峰帕丽达．阿布利孜. 激光照射对体外培养的婴儿血管瘤内皮细胞相关生长因子及细胞凋亡的影响[J]. 中华皮肤科杂志, 2021, 54(3): 232-235.
[15]	刘芳李璨宇方卉陈凤鸣刘宇王雷高天文坚哲. 婴幼儿先天性色素痣126例临床及病理特征分析[J]. 中华皮肤科杂志, 2021, 54(1): 42-49.

普萘洛尔治疗婴儿血管瘤的研究进展

Propranolol for the treatment of infantile hemangioma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 40

相关文章 15

Metrics

本文评价

推荐阅读 10